BioCryst Pharmaceuticals, Inc.
BCRX
$6.82
$0.416.40%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 12.34% | 7.09% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 12.34% | 7.09% | |||
| Cost of Revenue | 25.42% | 12.58% | |||
| Gross Profit | 4.38% | 4.00% | |||
| SG&A Expenses | 23.64% | 6.32% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 24.36% | 8.77% | |||
| Operating Income | -158.61% | -12.20% | |||
| Income Before Tax | -93.28% | -7.56% | |||
| Income Tax Expenses | 37.20% | 240.70% | |||
| Earnings from Continuing Operations | -90.94% | -10.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -90.94% | -10.72% | |||
| EBIT | -158.61% | -12.20% | |||
| EBITDA | -130.40% | -11.87% | |||
| EPS Basic | -90.56% | -10.42% | |||
| Normalized Basic EPS | -92.86% | -7.12% | |||
| EPS Diluted | -90.56% | -10.42% | |||
| Normalized Diluted EPS | -92.86% | -7.12% | |||
| Average Basic Shares Outstanding | 0.23% | 0.23% | |||
| Average Diluted Shares Outstanding | 0.23% | 0.23% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
